Ovarian serous cystadenocarcinoma

Summary

Ovarian serous cystadenocarcinoma (MONDO:0006046) is a disease with 1 cohort gene and 27 clinical trials. Molecularly, CCNE1 Amplification confers sensitivity to Akt Inhibitor MK2206 + Dinaciclib in Ovarian Serous Cystadenocarcinoma (CIViC Level D). Top therapeutic interventions include metformin, belinostat, and cyclophosphamide anhydrous.

At a glance

• Cohort genes: 1
• Clinical trials: 27
• Precision-medicine evidence (CIViC): 1 subtype–drug association

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	ovarian serous cystadenocarcinoma
Mondo ID	MONDO:0006046
EFO	EFO:1000043
DOID	DOID:5746
NCIT	C7978
UMLS	C0279663
MedGen	83541
GARD	0024274
Anatomy (UBERON)	UBERON:0000992
Is cancer (heuristic)	no

Also known as: ovarian serous cystadenocarcinoma

Data availability: 165 cell lines.

Disease family

Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › adenocarcinoma › ovarian adenocarcinoma › ovarian cystadenocarcinoma › ovarian serous cystadenocarcinoma

Related subtypes (2): ovarian mucinous cystadenocarcinoma, ovarian clear cell cystadenocarcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 0 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

Subset	Genes
civic_only	1

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
CCNE1	HGNC:1589	ENSG00000105173	P24864	G1/S-specific cyclin-E1	civic_evidence

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
CCNE1	G1/S-specific cyclin-E1	Essential for the control of the cell cycle at the G1/S (start) transition.

Protein-family classification

Druggable: 0 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Other/Unknown	1	1.8×	0.558

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
CCNE1	Other/Unknown	no		Cyclin_C-dom, Cyclin_N, Cyclin-like_dom

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	1
unknown	0

Top tissues across cohort

Tissue	Cohort genes
adrenal tissue	1
oocyte	1
secondary oocyte	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
CCNE1	201	ubiquitous	marker	secondary oocyte, oocyte, adrenal tissue

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
CCNE1	3,811

Structural data

PDB: 1 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
CCNE1	P24864	22

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 46. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes	1	2855.0×	0.007	CCNE1
PTK6 Regulates Cell Cycle	1	1903.3×	0.007	CCNE1
RHOBTB3 ATPase cycle	1	1142.0×	0.007	CCNE1
Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects	1	878.5×	0.007	CCNE1
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest	1	713.8×	0.007	CCNE1
p53-Dependent G1 DNA Damage Response	1	713.8×	0.007	CCNE1
p53-Dependent G1/S DNA damage checkpoint	1	713.8×	0.007	CCNE1
G1/S DNA Damage Checkpoints	1	671.8×	0.007	CCNE1
Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)	1	634.4×	0.007	CCNE1
TP53 Regulates Transcription of Cell Cycle Genes	1	543.8×	0.007	CCNE1
Signaling by PTK6	1	543.8×	0.007	CCNE1
Signaling by Non-Receptor Tyrosine Kinases	1	543.8×	0.007	CCNE1
G0 and Early G1	1	439.2×	0.007	CCNE1
Aberrant regulation of mitotic cell cycle due to RB1 defects	1	407.9×	0.007	CCNE1
G1 Phase	1	393.8×	0.007	CCNE1
Diseases of mitotic cell cycle	1	393.8×	0.007	CCNE1
G1/S-Specific Transcription	1	356.9×	0.007	CCNE1
Chaperonin-mediated protein folding	1	300.5×	0.007	CCNE1
Switching of origins to a post-replicative state	1	300.5×	0.007	CCNE1
Synthesis of DNA	1	300.5×	0.007	CCNE1
Association of TriC/CCT with target proteins during biosynthesis	1	292.8×	0.007	CCNE1
Cyclin E associated events during G1/S transition	1	285.5×	0.007	CCNE1
Cyclin A:Cdk2-associated events at S phase entry	1	265.6×	0.007	CCNE1
Protein folding	1	259.6×	0.007	CCNE1
DNA Replication	1	237.9×	0.007	CCNE1
G1/S Transition	1	233.1×	0.007	CCNE1
Cyclin D associated events in G1	1	233.1×	0.007	CCNE1
SCF(Skp2)-mediated degradation of p27/p21	1	207.6×	0.008	CCNE1
Mitotic G1 phase and G1/S transition	1	184.2×	0.008	CCNE1
S Phase	1	181.3×	0.008	CCNE1

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
positive regulation of mesenchymal stem cell proliferation	1	2106.5×	0.005	CCNE1
DNA replication initiation	1	624.1×	0.006	CCNE1
homologous chromosome pairing at meiosis	1	601.9×	0.006	CCNE1
positive regulation of G1/S transition of mitotic cell cycle	1	401.2×	0.007	CCNE1
telomere maintenance	1	267.5×	0.008	CCNE1
regulation of protein localization	1	205.5×	0.008	CCNE1
G1/S transition of mitotic cell cycle	1	200.6×	0.008	CCNE1
Wnt signaling pathway	1	99.7×	0.014	CCNE1
protein phosphorylation	1	68.0×	0.018	CCNE1
cell division	1	46.2×	0.024	CCNE1
negative regulation of transcription by RNA polymerase II	1	17.7×	0.056	CCNE1

Therapeutics

Drugs indicated for this disease

No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Belinostat, Carboplatin, Paclitaxel, Sargramostim.

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 0

Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
CCNE1	PALBOCICLIB

Top cohort targets by molecule count

Symbol	Molecules	Max phase
CCNE1	38	4

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
PALBOCICLIB	4	CCNE1
ABEMACICLIB	4	CCNE1
GILTERITINIB	4	CCNE1
TRILACICLIB	4	CCNE1
DINACICLIB	3	CCNE1
ALVOCIDIB	3	CCNE1
INDIGO	3	CCNE1
SILMITASERTIB	2	CCNE1
INDIRUBIN	2	CCNE1
SELICICLIB	2	CCNE1
ZOTIRACICLIB	2	CCNE1
NARAZACICLIB	2	CCNE1
CYC-065	2	CCNE1
BMS-919373	2	CCNE1
CROZBACICLIB	2	CCNE1
CT-7001	2	CCNE1
SIMUROSERTIB	2	CCNE1
RONICICLIB	2	CCNE1
EBVACICLIB	2	CCNE1
AT-7519	2	CCNE1
ZEMIRCICLIB	2	CCNE1
CULMERCICLIB	2	CCNE1
TEGTOCICLIB	2	CCNE1
MILCICLIB	2	CCNE1
BMS-754807	2	CCNE1
ASNUCICLIB	2	CCNE1
ISTISOCICLIB	2	CCNE1
PHA-793887	1	CCNE1
SU-9516	1	CCNE1
BMS-387032	1	CCNE1

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
CCNE1	691	Binding:690, ADMET:1

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
CCNE1	691

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

30 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
PALBOCICLIB	4	CCNE1
ABEMACICLIB	4	CCNE1
GILTERITINIB	4	CCNE1
TRILACICLIB	4	CCNE1
DINACICLIB	3	CCNE1
ALVOCIDIB	3	CCNE1
INDIGO	3	CCNE1
SILMITASERTIB	2	CCNE1
INDIRUBIN	2	CCNE1
SELICICLIB	2	CCNE1
ZOTIRACICLIB	2	CCNE1
NARAZACICLIB	2	CCNE1
CYC-065	2	CCNE1
BMS-919373	2	CCNE1
CROZBACICLIB	2	CCNE1
CT-7001	2	CCNE1
SIMUROSERTIB	2	CCNE1
RONICICLIB	2	CCNE1
EBVACICLIB	2	CCNE1
AT-7519	2	CCNE1
ZEMIRCICLIB	2	CCNE1
CULMERCICLIB	2	CCNE1
TEGTOCICLIB	2	CCNE1
MILCICLIB	2	CCNE1
BMS-754807	2	CCNE1
ASNUCICLIB	2	CCNE1
ISTISOCICLIB	2	CCNE1
PHA-793887	1	CCNE1
SU-9516	1	CCNE1
BMS-387032	1	CCNE1

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	1	CCNE1
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	0

Undrugged target profiles

0 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Clinical trials & evidence

Clinical trials

Clinical trials: 27.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	12
PHASE2	8
Not specified	4
PHASE3	1
PHASE1/PHASE2	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01492920	PHASE3	WITHDRAWN	Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy
NCT02101775	PHASE2	ACTIVE_NOT_RECRUITING	Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT00004221	PHASE2	TERMINATED	Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer
NCT00059787	PHASE2	COMPLETED	Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma
NCT00466960	PHASE2	COMPLETED	Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy
NCT00939809	PHASE2	COMPLETED	A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
NCT00993616	PHASE2	COMPLETED	Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin
NCT02122185	PHASE2	COMPLETED	Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02283658	PHASE2	COMPLETED	Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
NCT05074472	PHASE1/PHASE2	COMPLETED	A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors
NCT02142803	PHASE1	ACTIVE_NOT_RECRUITING	TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
NCT00002913	PHASE1	COMPLETED	Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer
NCT00060359	PHASE1	COMPLETED	Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer
NCT00079430	PHASE1	COMPLETED	Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
NCT00085358	PHASE1	COMPLETED	Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)
NCT00357448	PHASE1	COMPLETED	Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer
NCT00814086	PHASE1	COMPLETED	Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
NCT01074411	PHASE1	COMPLETED	Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
NCT01294293	PHASE1	COMPLETED	TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
NCT01459380	PHASE1	COMPLETED	Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
NCT01489371	PHASE1	COMPLETED	EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
NCT02050009	PHASE1	WITHDRAWN	Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02111941	EARLY_PHASE1	COMPLETED	Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
NCT00053235	Not specified	WITHDRAWN	Research Study in Patients With Advanced Ovarian Epithelial Cancer
NCT00897442	Not specified	COMPLETED	Collecting Tumor Samples From Patients With Gynecological Tumors
NCT01080521	Not specified	COMPLETED	Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy
NCT01275664	Not specified	TERMINATED	Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
METFORMIN	4	2
BELINOSTAT	4	1
CYCLOPHOSPHAMIDE ANHYDROUS	4	1
DENILEUKIN DIFTITOX	4	1
ERLOTINIB	4	1
GRANISETRON	4	1
TOPOTECAN HYDROCHLORIDE	4	1
VELIPARIB	3	2
ACETYLCARNITINE	3	1
PACLITAXEL POLIGLUMEX	3	1
ADAVOSERTIB	2	1
IBENTATUG	2	1
SAPANISERTIB	2	1
CHEMBL3962632	0	1
CHEMBL3991933	0	1
CHEMBL399538	0	1

Precision-medicine subtype map (CIViC)

Drug × molecular subtype: 1 predictive associations from 1 curated evidence items.

Molecular subtype	Therapy	Effect	Level	CIViC
CCNE1 Amplification	Akt Inhibitor MK2206 + Dinaciclib	Sensitivity/Response	CIViC D	EID1735